{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T22:34:33Z","timestamp":1791585273303,"version":"4.3.4"},"reference-count":98,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bone"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1016\/j.bone.2020.115407","type":"journal-article","created":{"date-parts":[[2020,5,6]],"date-time":"2020-05-06T17:47:55Z","timestamp":1588787275000},"page":"115407","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"special_numbering":"C","title":["History of risedronate"],"prefix":"10.1016","volume":"137","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7827-0778","authenticated-orcid":false,"given":"Michael R.","family":"McClung","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank H.","family":"Ebetino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3899","key":"10.1016\/j.bone.2020.115407_bb0005","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1126\/science.165.3899.1264","article-title":"Diphosphonates inhibit formation of calcium phosphate crystals in vitro and pathological calcification in vivo","volume":"165","author":"Francis","year":"1969","journal-title":"Science (New York, N.Y.)"},{"issue":"6","key":"10.1016\/j.bone.2020.115407_bb0010","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1007\/s00198-007-0540-8","article-title":"Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy","volume":"19","author":"Russell","year":"2008","journal-title":"Osteoporos. Int."},{"issue":"11","key":"10.1016\/j.bone.2020.115407_bb0015","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1359\/jbmr.1998.13.11.1668","article-title":"Heterocycle-containing bisphosphonates cause apoptosis and inhibit bone resorption by preventing protein prenylation: evidence from structure-activity relationships in J774 macrophages","volume":"13","author":"Luckman","year":"1998","journal-title":"J. Bone Miner. Res."},{"issue":"7","key":"10.1016\/j.bone.2020.115407_bb0020","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1021\/jm7015733","article-title":"Structure-activity relationships among the nitrogen containing bisphosphonates in clinical use and other analogues: time-dependent inhibition of human farnesyl pyrophosphate synthase","volume":"51","author":"Dunford","year":"2008","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bone.2020.115407_bb0025","series-title":"Symposium CEMO","first-page":"1","article-title":"The physical chemistry of the diphosphonates - its relationship to their medical activity","author":"Benedict","year":"1982"},{"issue":"9","key":"10.1016\/j.bone.2020.115407_bb0030","first-page":"389","article-title":"Antiresorptive dose-response relationships across three generations of bisphosphonates","volume":"15","author":"Sietsema","year":"1989","journal-title":"Drugs Exp. Clin. Res."},{"issue":"1","key":"10.1016\/j.bone.2020.115407_bb0035","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.bone.2011.04.022","article-title":"Bisphosphonates: the first 40 years","volume":"49","author":"Russell","year":"2011","journal-title":"Bone"},{"issue":"S1","key":"10.1016\/j.bone.2020.115407_bb0040","first-page":"S31","article-title":"A structure\/activity study of nitrogen heterocycle containing bisphosphonates as bone resorption inhibitors","volume":"38","author":"Benedict","year":"1986","journal-title":"Calcif Tissue Inter"},{"issue":"1","key":"10.1016\/j.bone.2020.115407_bb0045","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1080\/10426509908546169","article-title":"The discovery of the bone-active agent risedronate, and bisphosphonate structure-activity considerations including the aminophenylethane phosphonate series","volume":"144","author":"Ebetino","year":"1999","journal-title":"Phosphorus Sulfur Silicon Relat. Elem."},{"issue":"1","key":"10.1016\/j.bone.2020.115407_bb0050","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.bone.2011.03.774","article-title":"The relationship between the chemistry and biological activity of the bisphosphonates","volume":"49","author":"Ebetino","year":"2011","journal-title":"Bone"},{"key":"10.1016\/j.bone.2020.115407_bb0055","first-page":"265","article-title":"Bisphosphonates: structure-activity relationships and therapeutic implications","volume":"8","author":"Geddes","year":"1994","journal-title":"Bone and Mineral Research"},{"key":"10.1016\/j.bone.2020.115407_bb0060","series-title":"Osteoporosis 1990, 3, 3rd Int. Symposium on Osteoporosis, Copenhagen, Denmark","first-page":"1344","article-title":"Studies on a potent new antiresorptive bisphosphonate class: cis-octahydro-1-pyrindine-6,6-bisphosphonic acid, Ne-58025 and its analogues","author":"Ebetino","year":"1990"},{"issue":"4","key":"10.1016\/j.bone.2020.115407_bb0065","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1248\/cpb.41.688","article-title":"Studies on novel bone resorption inhibitors. I. Synthesis and pharmacological activities of aminomethylenebisphosphonate derivatives","volume":"41","author":"Takeuchi","year":"1993","journal-title":"Chemical & Pharmaceutical Bulletin"},{"key":"10.1016\/j.bone.2020.115407_bb0070","series-title":"New N-Peptidyl-amino-alkane-1,1-diphosphonic Acid Derivatives Useful for Treating Disorders of Calcium Metabolism. US Pat. 4666895","author":"Boises","year":"1985"},{"key":"10.1016\/j.bone.2020.115407_bb0075","unstructured":"Ebetino FH, Boeckman RK, Song X. (1R,6S)-2-Azabicyclo[4.3.0] nonane-8,8-diphosphonic acid and its use in treating or preventing bone disorders, for example, osteoporosis or Pagets disease. U.S. Pat. Appl. Publ. WO\/2008\/076417, 6-26-2008. U.S. Pat. 7,781,481. 2010."},{"key":"10.1016\/j.bone.2020.115407_bb0080","series-title":"Bisphosphonate on Bones","first-page":"139","article-title":"Bisphosphonate antiresorptive structure activity relationships","author":"Ebetino","year":"1995"},{"issue":"1\u20134","key":"10.1016\/j.bone.2020.115407_bb0085","first-page":"217","article-title":"Elucidation of a harmacophore for the bisphosphonate mechanism of bone antiresorptive activity","volume":"109","author":"Ebetino","year":"1996","journal-title":"Phosphorus Sulfur Silicon Relat. Elem."},{"issue":"45","key":"10.1016\/j.bone.2020.115407_bb0090","doi-asserted-by":"crossref","first-page":"14485","DOI":"10.1021\/ja061737c","article-title":"Solid-state NMR, crystallographic, and computational investigation of bisphosphonates and farnesyl diphosphate synthase-bisphosphonate complexes","volume":"128","author":"Mao","year":"2006","journal-title":"J. Am. Chem. Soc."},{"issue":"18","key":"10.1016\/j.bone.2020.115407_bb0095","doi-asserted-by":"crossref","first-page":"5594","DOI":"10.1021\/jm800325y","article-title":"Inhibition of geranylgeranyl diphosphate synthase by bisphosphonates: a crystallographic and computational investigation","volume":"51","author":"Chen","year":"2008","journal-title":"J. Med. Chem."},{"issue":"20","key":"10.1016\/j.bone.2020.115407_bb0100","doi-asserted-by":"crossref","first-page":"7829","DOI":"10.1073\/pnas.0601643103","article-title":"The molecular mechanism of nitrogen-containing bisphosphonates as antiosteoporosis drugs","volume":"103","author":"Kavanagh","year":"2006","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"1","key":"10.1016\/j.bone.2020.115407_bb0105","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1002\/jbm.b.31500","article-title":"Differences between bisphosphonates in binding affinities for hydroxyapatite","volume":"92B","author":"Lawson","year":"2010","journal-title":"J Biomed Mater Res B Appl Biomater"},{"issue":"S1","key":"10.1016\/j.bone.2020.115407_bb0110","article-title":"Bisphosphonate affinity to hydroxyapatite influences in vivo efficacy","volume":"22","author":"Lundy","year":"2007","journal-title":"J. Bone and Mineral Research"},{"issue":"9","key":"10.1016\/j.bone.2020.115407_bb0115","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1002\/jbmr.3138","article-title":"The pharmacological profile of a novel highly potent bisphosphonate, OX14 (1-fluoro-2-(imidazo-[1,2-alpha]pyridin-3-yl)-ethyl-bisphosphonate)","volume":"32","author":"Lawson","year":"2017","journal-title":"J. Bone Miner. Res."},{"issue":"10","key":"10.1016\/j.bone.2020.115407_bb0120","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1002\/jbmr.5650101008","article-title":"Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo","volume":"10","author":"Hughes","year":"1995","journal-title":"J. Bone Miner. Res."},{"issue":"4","key":"10.1016\/j.bone.2020.115407_bb0125","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1359\/jbmr.1998.13.4.581","article-title":"Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras","volume":"13","author":"Luckman","year":"1998","journal-title":"J. Bone Miner. Res."},{"issue":"4","key":"10.1016\/j.bone.2020.115407_bb0130","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1002\/jbmr.5650060410","article-title":"Estrogen and diphosphonate treatment provide long-term protection against osteopenia in ovariectomized rats","volume":"6","author":"Wronski","year":"1991","journal-title":"J. Bone Miner. Res."},{"issue":"2","key":"10.1016\/j.bone.2020.115407_bb0135","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1210\/endo-125-2-810","article-title":"Endocrine and pharmacological suppressors of bone turnover protect against osteopenia in ovariectomized rats","volume":"125","author":"Wronski","year":"1989","journal-title":"Endocrinology"},{"issue":"3","key":"10.1016\/j.bone.2020.115407_bb0140","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1007\/BF01321840","article-title":"Skeletal effects of withdrawal of estrogen and diphosphonate treatment in ovariectomized rats","volume":"53","author":"Wronski","year":"1993","journal-title":"Calcif. Tissue Int."},{"issue":"5","key":"10.1016\/j.bone.2020.115407_bb0145","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/8756-3282(94)90272-0","article-title":"Effects of prostaglandin E2 and risedronate administration on cancellous bone in older female rats","volume":"15","author":"Lin","year":"1994","journal-title":"Bone"},{"issue":"5","key":"10.1016\/j.bone.2020.115407_bb0150","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1002\/jbmr.5650110508","article-title":"Effects of intermittent hPTH(1-34) alone and in combination with 1,25(OH)(2)D(3) or risedronate on endosteal bone remodeling in canine cancellous and cortical bone","volume":"11","author":"Boyce","year":"1996","journal-title":"J. Bone Miner. Res."},{"issue":"4","key":"10.1016\/j.bone.2020.115407_bb0155","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1007\/s002239900438","article-title":"Bisphosphonate maintains parathyroid hormone (1-34)-induced cortical bone mass and mechanical strength in old rats","volume":"62","author":"Ejersted","year":"1998","journal-title":"Calcif. Tissue Int."},{"issue":"2","key":"10.1016\/j.bone.2020.115407_bb0160","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1002\/jbmr.5650100207","article-title":"The effects of risedronate on canine cancellous bone remodeling: three-dimensional kinetic reconstruction of the remodeling site","volume":"10","author":"Boyce","year":"1995","journal-title":"J. Bone Miner. Res."},{"issue":"7","key":"10.1016\/j.bone.2020.115407_bb0165","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1359\/jbmr.2002.17.7.1139","article-title":"Risedronate preserves trabecular architecture and increases bone strength in vertebra of ovariectomized minipigs as measured by three-dimensional microcomputed tomography","volume":"17","author":"Borah","year":"2002","journal-title":"J. Bone Miner. Res."},{"issue":"5","key":"10.1016\/j.bone.2020.115407_bb0170","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/s00223-002-2104-4","article-title":"Risedronate preserves bone architecture in early postmenopausal women in 1 year as measured by three-dimensional microcomputed tomography","volume":"73","author":"Dufresne","year":"2003","journal-title":"Calcif. Tissue Int."},{"issue":"3","key":"10.1016\/j.bone.2020.115407_bb0175","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1177\/00912700022008928","article-title":"Dose-proportional pharmacokinetics of risedronate on single-dose oral administration to healthy volunteers","volume":"40","author":"Mitchell","year":"2000","journal-title":"J. Clin. Pharmacol."},{"issue":"2","key":"10.1016\/j.bone.2020.115407_bb0180","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1023\/A:1011024200280","article-title":"Risedronate pharmacokinetics and intra- and inter-subject variability upon single-dose intravenous and oral administration","volume":"18","author":"Mitchell","year":"2001","journal-title":"Pharm. Res."},{"issue":"4","key":"10.1016\/j.bone.2020.115407_bb0185","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1046\/j.1365-2125.1999.00035.x","article-title":"The effect of dosing regimen on the pharmacokinetics of risedronate","volume":"48","author":"Mitchell","year":"1999","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"1","key":"10.1016\/j.bone.2020.115407_bb0190","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/8756-3282(94)90890-7","article-title":"Biologic, histologic and densitometric effects of oral risedronate on bone in patients with multiple myeloma","volume":"15","author":"Roux","year":"1994","journal-title":"Bone"},{"issue":"4","key":"10.1016\/j.bone.2020.115407_bb0195","first-page":"1067","article-title":"Acute changes in calcium homeostasis during treatment of primary hyperparathyroidism with risedronate","volume":"77","author":"Reasner","year":"1993","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"4","key":"10.1016\/j.bone.2020.115407_bb0200","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/0049-0172(94)90060-4","article-title":"Risedronate in Paget\u2019s disease: preliminary results of a multicenter study","volume":"23","author":"Brown","year":"1994","journal-title":"Semin. Arthritis Rheum."},{"issue":"2","key":"10.1016\/j.bone.2020.115407_bb0205","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s002239900584","article-title":"Risedronate, a highly effective, short-term oral treatment for Paget\u2019s disease: a dose-response study","volume":"64","author":"Brown","year":"1999","journal-title":"Calcif. Tissue Int."},{"issue":"6","key":"10.1016\/j.bone.2020.115407_bb0210","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1359\/jbmr.1998.13.6.1032","article-title":"Risedronate in the treatment of Paget\u2019s disease of bone: an open label, multicenter study","volume":"13","author":"Siris","year":"1998","journal-title":"J. Bone Miner. Res."},{"issue":"5","key":"10.1016\/j.bone.2020.115407_bb0215","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/S0002-9343(99)00062-5","article-title":"A randomized, double-blind comparison of risedronate and etidronate in the treatment of Paget\u2019s disease of bone. Paget\u2019s Risedronate\/Etidronate Study Group","volume":"106","author":"Miller","year":"1999","journal-title":"Am. J. Med."},{"issue":"3","key":"10.1016\/j.bone.2020.115407_bb0220","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S8756-3282(96)00364-X","article-title":"Alendronate in the treatment of Paget\u2019s disease of bone","volume":"20","author":"Khan","year":"1997","journal-title":"Bone"},{"issue":"9","key":"10.1016\/j.bone.2020.115407_bb0225","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1056\/NEJMoa044241","article-title":"Comparison of a single infusion of zoledronic acid with risedronate for Paget\u2019s disease","volume":"353","author":"Reid","year":"2005","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.bone.2020.115407_bb0230","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1056\/NEJM199007123230201","article-title":"Intermittent cyclical etidronate treatment of postmenopausal osteoporosis","volume":"323","author":"Watts","year":"1990","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bone.2020.115407_bb0235","doi-asserted-by":"crossref","first-page":"115222","DOI":"10.1016\/j.bone.2020.115222","article-title":"History of etidronate","volume":"134","author":"Watts","year":"2020","journal-title":"Bone"},{"issue":"9","key":"10.1016\/j.bone.2020.115407_bb0240","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1002\/jbmr.5650080915","article-title":"Vertebral fracture assessment using a semiquantitative technique","volume":"8","author":"Genant","year":"1993","journal-title":"J. Bone Miner. Res."},{"issue":"4","key":"10.1016\/j.bone.2020.115407_bb0245","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1007\/BF01774010","article-title":"Quality control of DXA instruments in multicenter trials","volume":"5","author":"Faulkner","year":"1995","journal-title":"Osteoporos. Int."},{"issue":"8","key":"10.1016\/j.bone.2020.115407_bb0250","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1002\/jbmr.5650090802","article-title":"The diagnosis of osteoporosis","volume":"9","author":"Kanis","year":"1994","journal-title":"J. Bone Miner. Res."},{"issue":"8837","key":"10.1016\/j.bone.2020.115407_bb0255","first-page":"72","article-title":"Bone density at various sites for prediction of hip fractures","volume":"341","author":"Cummings","year":"1993","journal-title":"The Study of Osteoporotic Fractures Research Group. Lancet."},{"issue":"2","key":"10.1016\/j.bone.2020.115407_bb0260","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/S0002-9343(99)80134-X","article-title":"Alendronate treatment of the postmenopausal osteoporotic woman: effect of multiple dosages on bone mass and bone remodeling","volume":"99","author":"Chesnut","year":"1995","journal-title":"Am. J. Med."},{"issue":"22","key":"10.1016\/j.bone.2020.115407_bb0265","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1056\/NEJM199511303332201","article-title":"Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group","volume":"333","author":"Liberman","year":"1995","journal-title":"N. Engl. J. Med."},{"issue":"9041","key":"10.1016\/j.bone.2020.115407_bb0270","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1016\/S0140-6736(96)07088-2","article-title":"Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group","volume":"348","author":"Black","year":"1996","journal-title":"Lancet"},{"issue":"24","key":"10.1016\/j.bone.2020.115407_bb0275","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1001\/jama.280.24.2077","article-title":"Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial","volume":"280","author":"Cummings","year":"1998","journal-title":"Jama"},{"issue":"3","key":"10.1016\/j.bone.2020.115407_bb0280","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1200\/JCO.1997.15.3.955","article-title":"Bisphosphonate risedronate prevents bone loss in women with artificial menopause due to chemotherapy of breast cancer: a double-blind, placebo-controlled study","volume":"15","author":"Delmas","year":"1997","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.bone.2020.115407_bb0285","first-page":"396","article-title":"Risedronate increases bone mass in an early postmenopausal population: two years of treatment plus one year of follow-up","volume":"83","author":"Mortensen","year":"1998","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"5","key":"10.1016\/j.bone.2020.115407_bb0290","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1007\/PL00004152","article-title":"A 2-year phase II study with 1-year of follow-up of risedronate (NE-58095) in postmenopausal osteoporosis","volume":"7","author":"Clemmesen","year":"1997","journal-title":"Osteoporos. Int."},{"issue":"14","key":"10.1016\/j.bone.2020.115407_bb0295","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1001\/jama.282.14.1344","article-title":"Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group","volume":"282","author":"Harris","year":"1999","journal-title":"Jama"},{"issue":"1","key":"10.1016\/j.bone.2020.115407_bb0300","first-page":"83","article-title":"Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis","volume":"11","author":"Reginster","year":"2000","journal-title":"Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int."},{"issue":"6","key":"10.1016\/j.bone.2020.115407_bb0305","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1007\/s00223-004-0286-7","article-title":"Seven years of treatment with risedronate in women with postmenopausal osteoporosis","volume":"75","author":"Mellstrom","year":"2004","journal-title":"Calcif. Tissue Int."},{"issue":"S1","key":"10.1016\/j.bone.2020.115407_bb0310","first-page":"S471","article-title":"Risedronate is effective in increasing BMD in both early and late postmenopausal women with low bone mass","volume":"12","author":"MM","year":"1997","journal-title":"J. Bone Miner. Res."},{"issue":"5","key":"10.1016\/j.bone.2020.115407_bb0315","first-page":"1895","article-title":"Risedronate reverses bone loss in postmenopausal women with low bone mass: results from a multinational, double-blind, placebo-controlled trial. BMD-MN Study Group","volume":"85","author":"Fogelman","year":"2000","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"11","key":"10.1016\/j.bone.2020.115407_bb0320","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1002\/1529-0131(199911)42:11<2309::AID-ANR8>3.0.CO;2-K","article-title":"Risedronate therapy prevents corticosteroid-induced bone loss: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study","volume":"42","author":"Cohen","year":"1999","journal-title":"Arthritis Rheum."},{"issue":"6","key":"10.1016\/j.bone.2020.115407_bb0325","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1359\/jbmr.2000.15.6.1006","article-title":"Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomized trial. European Corticosteroid-Induced Osteoporosis Treatment Study","volume":"15","author":"Reid","year":"2000","journal-title":"J. Bone Miner. Res."},{"issue":"5","key":"10.1016\/j.bone.2020.115407_bb0330","first-page":"1890","article-title":"Effect of combined risedronate and hormone replacement therapies on bone mineral density in postmenopausal women","volume":"86","author":"Harris","year":"2001","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"5","key":"10.1016\/j.bone.2020.115407_bb0335","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1002\/jbmr.5650100517","article-title":"Prevalence of low femoral bone density in older U.S. women from NHANES III","volume":"10","author":"Looker","year":"1995","journal-title":"J. Bone Miner. Res."},{"issue":"5","key":"10.1016\/j.bone.2020.115407_bb0340","first-page":"333","article-title":"Effect of risedronate on the risk of hip fracture in elderly women","volume":"344","author":"McClung","year":"2001","journal-title":"Hip Intervention Program Study Group. The New England Journal of Medicine."},{"issue":"S2","key":"10.1016\/j.bone.2020.115407_bb0345","first-page":"152","article-title":"Risedronate rapidly reduces vertebral fracture risk in patients with varying degrees of osteoporotic severity","volume":"11","author":"Eastell","year":"2000","journal-title":"Osteopor Int"},{"issue":"S1","key":"10.1016\/j.bone.2020.115407_bb0350","first-page":"S226","article-title":"Rapid and consistent effect of risedronate on the reduction of vertebral fracture risk in patients with varying degrees of osteoporotic severity","volume":"15","author":"Harris","year":"2000","journal-title":"J. Bone Miner. Res."},{"issue":"11","key":"10.1016\/j.bone.2020.115407_bb0355","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1111\/j.1532-5415.2004.52506.x","article-title":"Safety and efficacy of risedronate in reducing fracture risk in osteoporotic women aged 80 and older: implications for the use of antiresorptive agents in the old and oldest old","volume":"52","author":"Boonen","year":"2004","journal-title":"J. Am. Geriatr. Soc."},{"issue":"3","key":"10.1016\/j.bone.2020.115407_bb0360","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/s001980050061","article-title":"How hip and whole-body bone mineral density predict hip fracture in elderly women: the EPIDOS Prospective Study","volume":"8","author":"Schott","year":"1998","journal-title":"Osteoporos. Int."},{"issue":"Suppl. 2","key":"10.1016\/j.bone.2020.115407_bb0365","doi-asserted-by":"crossref","first-page":"S22","DOI":"10.1016\/S1098-3597(03)90044-5","article-title":"Pathogenesis of osteoporotic hip fractures","author":"McClung","year":"2003","journal-title":"Clinical Cornerstone"},{"issue":"6","key":"10.1016\/j.bone.2020.115407_bb0370","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1007\/BF01629574","article-title":"Discrepancies in normative data between Lunar and Hologic DXA systems","volume":"6","author":"Faulkner","year":"1996","journal-title":"Osteoporos. Int."},{"issue":"1","key":"10.1016\/j.bone.2020.115407_bb0375","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1359\/JBMR.040920","article-title":"Treatment with once-weekly alendronate 70 mg compared with once-weekly risedronate 35 mg in women with postmenopausal osteoporosis: a randomized double-blind study","volume":"20","author":"Rosen","year":"2005","journal-title":"J. Bone Miner. Res."},{"issue":"12","key":"10.1016\/j.bone.2020.115407_bb0380","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1185\/030079904X16768","article-title":"Response to therapy with once-weekly alendronate 70 mg compared to once-weekly risedronate 35 mg in the treatment of postmenopausal osteoporosis","volume":"20","author":"Sebba","year":"2004","journal-title":"Curr. Med. Res. Opin."},{"issue":"2","key":"10.1016\/j.bone.2020.115407_bb0385","doi-asserted-by":"crossref","first-page":"63","DOI":"10.2165\/00044011-200626020-00002","article-title":"Alendronic acid produces greater effects than risedronic acid on bone density and turnover in postmenopausal women with osteoporosis: results of FACTS-international","volume":"26","author":"Reid","year":"2006","journal-title":"Clinical Drug Investigation"},{"issue":"12","key":"10.1016\/j.bone.2020.115407_bb0390","doi-asserted-by":"crossref","first-page":"2951","DOI":"10.1185\/03007990903361307","article-title":"Update on monthly oral bisphosphonate therapy for the treatment of osteoporosis: focus on ibandronate 150 mg and risedronate 150 mg","volume":"25","author":"Epstein","year":"2009","journal-title":"Curr. Med. Res. Opin."},{"issue":"1","key":"10.1016\/j.bone.2020.115407_bb0395","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s00198-015-3145-7","article-title":"Response of bone turnover markers to three oral bisphosphonate therapies in postmenopausal osteoporosis: the TRIO study","volume":"27","author":"Naylor","year":"2016","journal-title":"Osteoporos. Int."},{"issue":"12","key":"10.1016\/j.bone.2020.115407_bb0400","doi-asserted-by":"crossref","first-page":"2729","DOI":"10.1007\/s00198-014-2817-z","article-title":"Comparison of the effects of three oral bisphosphonate therapies on the peripheral skeleton in postmenopausal osteoporosis: the TRIO study","volume":"25","author":"Paggiosi","year":"2014","journal-title":"Osteoporos. Int."},{"issue":"4","key":"10.1016\/j.bone.2020.115407_bb0405","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/j.bone.2003.12.013","article-title":"Risedronate preserves bone architecture in postmenopausal women with osteoporosis as measured by three-dimensional microcomputed tomography","volume":"34","author":"Borah","year":"2004","journal-title":"Bone"},{"issue":"2","key":"10.1016\/j.bone.2020.115407_bb0410","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.bone.2006.01.161","article-title":"Long-term risedronate treatment normalizes mineralization and continues to preserve trabecular architecture: sequential triple biopsy studies with micro-computed tomography","volume":"39","author":"Borah","year":"2006","journal-title":"Bone"},{"issue":"1","key":"10.1016\/j.bone.2020.115407_bb0415","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1359\/jbmr.090711","article-title":"Risedronate reduces intracortical porosity in women with osteoporosis","volume":"25","author":"Borah","year":"2010","journal-title":"J. Bone Miner. Res."},{"issue":"3","key":"10.1016\/j.bone.2020.115407_bb0420","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s00198-007-0460-7","article-title":"Fracture risk r6mains reduced one year after discontinuation of risedronate","volume":"19","author":"Watts","year":"2008","journal-title":"Osteoporos. Int."},{"issue":"11","key":"10.1016\/j.bone.2020.115407_bb0425","doi-asserted-by":"crossref","first-page":"3367","DOI":"10.1210\/jc.2011-0412","article-title":"Effect of stopping risedronate after long-term treatment on bone turnover","volume":"96","author":"Eastell","year":"2011","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"4","key":"10.1016\/j.bone.2020.115407_bb0430","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S0002-9343(97)00130-7","article-title":"Increments in bone mineral density of the lumbar spine and hip and suppression of bone turnover are maintained after discontinuation of alendronate in postmenopausal women","volume":"103","author":"Stock","year":"1997","journal-title":"Am. J. Med."},{"issue":"6 Pt 1","key":"10.1016\/j.bone.2020.115407_bb0435","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1097\/01.GME.0000123641.76105.B5","article-title":"Changes in bone density and turnover after alendronate or estrogen withdrawal","volume":"11","author":"Wasnich","year":"2004","journal-title":"Menopause"},{"issue":"3","key":"10.1016\/j.bone.2020.115407_bb0440","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s00198-002-1369-9","article-title":"A double-blind dose-ranging study of risedronate in Japanese patients with osteoporosis (a study by the Risedronate Late Phase II Research Group)","volume":"14","author":"Shiraki","year":"2003","journal-title":"Osteoporos. Int."},{"issue":"4","key":"10.1016\/j.bone.2020.115407_bb0445","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1359\/jbmr.081214","article-title":"Once-weekly risedronate in men with osteoporosis: results of a 2-year, placebo-controlled, double-blind, multicenter study","volume":"24","author":"Boonen","year":"2009","journal-title":"J. Bone Miner. Res."},{"issue":"4","key":"10.1016\/j.bone.2020.115407_bb0450","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s002230001146","article-title":"Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy","volume":"67","author":"Wallach","year":"2000","journal-title":"Calcif. Tissue Int."},{"issue":"2","key":"10.1016\/j.bone.2020.115407_bb0455","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s00223-002-2011-8","article-title":"The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis","volume":"71","author":"Brown","year":"2002","journal-title":"Calcif. Tissue Int."},{"issue":"7","key":"10.1016\/j.bone.2020.115407_bb0460","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1007\/s00198-007-0531-9","article-title":"Monthly dosing of 75 mg risedronate on 2 consecutive days a month: efficacy and safety results","volume":"19","author":"Delmas","year":"2008","journal-title":"Osteoporos. Int."},{"issue":"1","key":"10.1016\/j.bone.2020.115407_bb0465","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s00223-012-9668-4","article-title":"A novel monthly dosing regimen of risedronate for the treatment of postmenopausal osteoporosis: 2-year data","volume":"92","author":"McClung","year":"2013","journal-title":"Calcif. Tissue Int."},{"issue":"1","key":"10.1016\/j.bone.2020.115407_bb0470","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.bone.2007.09.001","article-title":"Efficacy and safety of risedronate 150 mg once a month in the treatment of postmenopausal osteoporosis","volume":"42","author":"Delmas","year":"2008","journal-title":"Bone"},{"issue":"1","key":"10.1016\/j.bone.2020.115407_bb0475","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/s00198-012-2056-0","article-title":"Efficacy and safety of risedronate 150-mg once a month in the treatment of postmenopausal osteoporosis: 2-year data","volume":"24","author":"McClung","year":"2013","journal-title":"Osteoporos. Int."},{"issue":"12","key":"10.1016\/j.bone.2020.115407_bb0480","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.1185\/030079906X154042","article-title":"Patient preference and adherence: comparative US studies between two bisphosphonates, weekly risedronate and monthly ibandronate","volume":"22","author":"Gold","year":"2006","journal-title":"Curr. Med. Res. Opin."},{"issue":"1","key":"10.1016\/j.bone.2020.115407_bb0485","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/s00198-011-1791-y","article-title":"Efficacy and safety of a novel delayed-release risedronate 35 mg once-a-week tablet","volume":"23","author":"McClung","year":"2012","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.bone.2020.115407_bb0490","author":"The Procter & Gamble Company v"}],"container-title":["Bone"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328220301873?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328220301873?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T17:51:36Z","timestamp":1757613096000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S8756328220301873"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8]]},"references-count":98,"alternative-id":["S8756328220301873"],"URL":"https:\/\/doi.org\/10.1016\/j.bone.2020.115407","relation":{},"ISSN":["8756-3282"],"issn-type":[{"value":"8756-3282","type":"print"}],"subject":[],"published":{"date-parts":[[2020,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"History of risedronate","name":"articletitle","label":"Article Title"},{"value":"Bone","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bone.2020.115407","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"115407"}}